menu
    • menu

    Find Aleniglipron manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    0

    USDMF

    0

    CEP/COS

    0

    JDMF

    0

    EU WC

    0

    KDMF

    0

    NDC API

    0

    VMF

    0

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    0

    FDF Dossiers

    0

    FDA Orange Book

    0

    Europe

    0

    Canada

    0

    Australia

    0

    South Africa

    0

    Listed Dossiers

    1PROSPECTS

    2DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    API/FDF Prices: Book a Demo

    API REF. PRICE (USD/KG)

    $
    $ 0

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    NA

    MARKET PLACE

    0

    API

    0

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    2

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Z6xcl6r9sx, 2685823-26-9, Refchem:1076327, Aleniglipron [inn], Orb2664969, Schembl23748580
    Molecular Formula
    C49H55FN9O6P
    Molecular Weight
    916.0  g/mol
    InChI Key
    CPOJUYUGONJVPZ-WIXASUBBSA-N
    FDA UNII
    Z6XCL6R9SX
    Aleniglipron
    1 2D Structure

    Aleniglipron

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[(1S,2S)-1-[2-[(4S)-3-[3-[4-diethylphosphoryl-3-(methylamino)phenyl]-2-oxoimidazol-1-yl]-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-5-(oxan-4-yl)indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one
    2.1.2 InChI
    InChI=1S/C49H55FN9O6P/c1-8-66(63,9-2)41-13-11-35(26-38(41)51-7)56-18-19-57(48(56)62)44-42-31(6)55(17-14-37(42)53-59(44)36-22-28(3)43(50)29(4)23-36)45(60)40-25-34-24-33(32-15-20-64-21-16-32)10-12-39(34)58(40)49(27-30(49)5)46-52-47(61)65-54-46/h10-13,18-19,22-26,30-32,51H,8-9,14-17,20-21,27H2,1-7H3,(H,52,54,61)/t30-,31-,49-/m0/s1
    2.1.3 InChI Key
    CPOJUYUGONJVPZ-WIXASUBBSA-N
    2.2 Other Identifiers
    2.2.1 UNII
    Z6XCL6R9SX
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Z6xcl6r9sx

    2. 2685823-26-9

    3. Refchem:1076327

    4. Aleniglipron [inn]

    5. Orb2664969

    6. Schembl23748580

    7. Schembl29981727

    8. Ex-a15126

    9. 1,2,4-oxadiazol-5(2h)-one, 3-[(1s,2s)-1-[2-[[(4s)-3-[3-[4-(diethylphosphinyl)-3-(methylamino)phenyl]-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-(tetrahydro-2h-pyran-4-yl)-1h-indol-1-yl]-2-methylcyclopropyl]-

    10. 3-((1s,2s)-1-(2-((s)-3-(3-(4-(diethylphosphoryl)-3-(methylamino)phenyl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2h-pyrazolo[4,3-c]pyridine-5-carbonyl)-5-(tetrahydro-2h-pyran-4-yl)-1h-indol-1-yl )-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4h)-one

    11. 3-[(1s,2s)-1-[2-[[(4s)-3-[3-[4-(diethylphosphinyl)-3-(methylamino)phenyl]-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-(tetrahydro-2h-pyran-4-yl)-1h-indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazol-5(2h)-one

    2.4 Create Date
    2022-08-27
    3 Chemical and Physical Properties
    Molecular Weight 916.0 g/mol
    Molecular Formula C49H55FN9O6P
    XLogP36.7
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count11
    Exact Mass Da
    Monoisotopic Mass Da
    Topological Polar Surface Area156
    Heavy Atom Count66
    Formal Charge0
    Complexity1950
    Isotope Atom Count0
    Defined Atom Stereocenter Count3
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

    Details:

    Aleniglipron is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of obesity.


    Lead Product(s): Aleniglipron,Inapplicable

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 10, 2026

    blank

    01

    Structure Therapeutics

    U.S.A
    arrow
    Health 2.0 Conference
    Not Confirmed

    Structure Therapeutics

    U.S.A
    arrow
    Health 2.0 Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Aleniglipron,Inapplicable

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

    Details : Aleniglipron is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of obesity.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    February 10, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aleniglipron Phase 2 Body Composition Study

    Details:

    Aleniglipron is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.


    Lead Product(s): Aleniglipron,Inapplicable

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 12, 2025

    blank

    02

    Structure Therapeutics

    U.S.A
    arrow
    Health 2.0 Conference
    Not Confirmed

    Structure Therapeutics

    U.S.A
    arrow
    Health 2.0 Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Aleniglipron,Inapplicable

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aleniglipron Phase 2 Body Composition Study

    Details : Aleniglipron is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 12, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search